Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: Implications for integrase inhibitors

AIDS Research and Human Retroviruses

Volumn 28, Issue 12, 2012, Pages 1788-1792

  Oliveira, Michelli F ^a   Ramalho, Dulce B ^a,b   Abreu, Celina M ^a   Vubil, Adolfo ^b   Mabunda, Nédio ^b   Ismael, Nalia ^b   Francisco, Cidia ^b   Jani, Ilesh V ^b   Tanuri, Amilcar ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR;

ARTICLE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MOZAMBIQUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS ISOLATION;

DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MOLECULAR SEQUENCE DATA; MOZAMBIQUE; MUTATION, MISSENSE; PROVIRUSES; SEQUENCE ANALYSIS, DNA;

EID: 84870020993     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0058     Document Type: Article

References (14)

1. AIDS Epidemic Update, 2009: http://www.unaids.org/en/dataanalysis/ epidemiology/2009aidsepidemicupdate/.
2. Instituto Nacional de Saúde (INS), Instituto Nacional de estatística (INE) e ICF Macro. 2010. Inquérito nacional de prevalência, riscos comportamentais e informação sobre o HIV e SIDA em Moçambique 2009. Calverton, Maryland, EUA: INS, INE e ICF Macro. (WWW.measuredhs.com).
3. World Health Organization: http://whqlibdoc.who.int/publications/2010/ 9789241599764-eng.pdf.
4. Dados de TARV Nacionais, Ministério de Saúde, Direcção de assistência médica, Mozambique. http://www.misau.gov.mz/pt/hiv-sida/dados-tarv-nacionais-de-nov-2010- a-abril-2011
5. Métifiot M, Marchand C, Maddali K, and Pommier Y: Resistance to Integrase Inhibitors. Viruses 2010;2:1347-1366.
6. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011;25(5):679-689.
7. Hunt GM, Papathanasopolous MA, Gray GE, and Tie-messen CT: Characterisation of near-full length genome sequences of three South African human immunodeficiency virus type 1 subtype C isolates. Virus Genes 2003;26:49-56.
8. Tzitzivacos DB, Tiemessen CT, Stevens WS, and Papatha-nasopoulos MA: Viral genetic determinants of nonpro-gressive HIV-1 subtype C infection in antiretroviral drug naive children. AIDS Res Hum Retroviruses 2009;25:1141-1148.
9. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, and Papathanasopoulos MA. Natural polymorphisms of in-tegrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses 2010;26(4):489-493.
10. Zhu K, Dobard C, and Chow SA: Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004;78:5045-5055.
11. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, and Shafer RW: Natural variation of HIV-1 group M in-tegrase: Implications for a new class of anti-retroviral inhibitors. Retrovirology 2008;5:74.
12. Reuman EC, Bachmann MH, Varghese V, Fessel WJ, and Shafer RW: Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother 2010;54(2):934-936.
13. Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, et al.: Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 2008;80(2):213-222.
14. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, Petropoulos CJ, and Huang W: Loss of ralte-gravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009;83(22):11440-11446.